BG107943A - 1,4-дизам...''...ни пип...разинови производни, пол...зни ка'о "ро'...л...к'ивни ал"а1-адр...но-...п'орни блок...ри - Google Patents
1,4-дизам...''...ни пип...разинови производни, пол...зни ка'о "ро'...л...к'ивни ал"а1-адр...но-...п'орни блок...ри Download PDFInfo
- Publication number
- BG107943A BG107943A BG107943A BG10794303A BG107943A BG 107943 A BG107943 A BG 107943A BG 107943 A BG107943 A BG 107943A BG 10794303 A BG10794303 A BG 10794303A BG 107943 A BG107943 A BG 107943A
- Authority
- BG
- Bulgaria
- Prior art keywords
- compound
- tetrahydro
- piperazin
- dione
- propyl
- Prior art date
Links
- -1 1,4-disubstituted piperazine Chemical class 0.000 title claims abstract description 47
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 title abstract 2
- 102000015009 alpha1-adrenergic receptor activity proteins Human genes 0.000 title abstract 2
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 74
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract description 21
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 230000003042 antagnostic effect Effects 0.000 claims abstract description 4
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 55
- CIFFBTOJCKSRJY-UHFFFAOYSA-N 3α,4,7,7α-tetrahydro-1h-isoindole-1,3(2h)-dione Chemical compound C1C=CCC2C(=O)NC(=O)C21 CIFFBTOJCKSRJY-UHFFFAOYSA-N 0.000 claims description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 16
- 239000002243 precursor Substances 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 8
- 150000001204 N-oxides Chemical class 0.000 claims description 8
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 239000002207 metabolite Substances 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 5
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 3
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 3
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 3
- 150000004885 piperazines Chemical class 0.000 claims description 3
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 claims 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 claims 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 claims 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims 1
- COTCIEJJLOJCFO-UHFFFAOYSA-N 2-[3-(4-benzylpiperazin-1-yl)propyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione Chemical compound O=C1C2CC=CCC2C(=O)N1CCCN(CC1)CCN1CC1=CC=CC=C1 COTCIEJJLOJCFO-UHFFFAOYSA-N 0.000 claims 1
- RPFLJFRMWVKIAS-UHFFFAOYSA-N 2-[3-[4-(2,5-dimethoxyphenyl)piperazin-1-yl]propyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione Chemical compound COC1=CC=C(OC)C(N2CCN(CCCN3C(C4CC=CCC4C3=O)=O)CC2)=C1 RPFLJFRMWVKIAS-UHFFFAOYSA-N 0.000 claims 1
- JCCNYJLQRFJJHK-UHFFFAOYSA-N 2-[3-[4-(3-phenylprop-2-enyl)piperazin-1-yl]propyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione Chemical compound O=C1C2CC=CCC2C(=O)N1CCCN(CC1)CCN1CC=CC1=CC=CC=C1 JCCNYJLQRFJJHK-UHFFFAOYSA-N 0.000 claims 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 claims 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 claims 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 claims 1
- 229940126657 Compound 17 Drugs 0.000 claims 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 claims 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims 1
- 229940125904 compound 1 Drugs 0.000 claims 1
- 229940125773 compound 10 Drugs 0.000 claims 1
- 229940125797 compound 12 Drugs 0.000 claims 1
- 229940126543 compound 14 Drugs 0.000 claims 1
- 229940125758 compound 15 Drugs 0.000 claims 1
- 229940126142 compound 16 Drugs 0.000 claims 1
- 229940125810 compound 20 Drugs 0.000 claims 1
- 229940126086 compound 21 Drugs 0.000 claims 1
- 229940126208 compound 22 Drugs 0.000 claims 1
- 229940125833 compound 23 Drugs 0.000 claims 1
- 229940125961 compound 24 Drugs 0.000 claims 1
- 229940125846 compound 25 Drugs 0.000 claims 1
- 229940125851 compound 27 Drugs 0.000 claims 1
- 229940127204 compound 29 Drugs 0.000 claims 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 208000024891 symptom Diseases 0.000 abstract description 7
- 239000002253 acid Substances 0.000 abstract description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 13
- 239000005557 antagonist Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 210000002307 prostate Anatomy 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 7
- VJTFJGINESSGAW-UHFFFAOYSA-N 3a,4,7,7a-tetrahydroisoindole-1,3-dione;hydrochloride Chemical compound Cl.C1C=CCC2C(=O)NC(=O)C21 VJTFJGINESSGAW-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000003202 urodynamic effect Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229960001802 phenylephrine Drugs 0.000 description 3
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 2
- 102000017910 Adrenergic receptor Human genes 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 2
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 2
- 102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 2
- 108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000009989 contractile response Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 2
- 229960001389 doxazosin Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
- 229960001289 prazosin Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 2
- 229960001693 terazosin Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- KMOUUZVZFBCRAM-OLQVQODUSA-N (3as,7ar)-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione Chemical compound C1C=CC[C@@H]2C(=O)OC(=O)[C@@H]21 KMOUUZVZFBCRAM-OLQVQODUSA-N 0.000 description 1
- DDMVHGULHRJOEC-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazin-1-ium;chloride Chemical compound Cl.COC1=CC=CC=C1N1CCNCC1 DDMVHGULHRJOEC-UHFFFAOYSA-N 0.000 description 1
- BRUIGSFNDPUVNI-UHFFFAOYSA-N 1-phenyl-2-(trifluoromethyl)piperazine Chemical class FC(F)(F)C1CNCCN1C1=CC=CC=C1 BRUIGSFNDPUVNI-UHFFFAOYSA-N 0.000 description 1
- YXTODIAELXJZHX-UHFFFAOYSA-N 2-[3-[4-(2-ethoxyphenyl)piperazin-1-yl]butyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione Chemical compound CCOC1=CC=CC=C1N1CCN(C(C)CCN2C(C3CC=CCC3C2=O)=O)CC1 YXTODIAELXJZHX-UHFFFAOYSA-N 0.000 description 1
- GEXAKHRGOWCMGV-UHFFFAOYSA-N 2-[3-[4-(2-ethoxyphenyl)piperazin-1-yl]butyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione;hydrochloride Chemical compound Cl.CCOC1=CC=CC=C1N1CCN(C(C)CCN2C(C3CC=CCC3C2=O)=O)CC1 GEXAKHRGOWCMGV-UHFFFAOYSA-N 0.000 description 1
- RFKMAUQMQSEPAM-UHFFFAOYSA-N 2-[3-[4-(2-hexoxyphenyl)piperazin-1-yl]propyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione Chemical compound CCCCCCOC1=CC=CC=C1N1CCN(CCCN2C(C3CC=CCC3C2=O)=O)CC1 RFKMAUQMQSEPAM-UHFFFAOYSA-N 0.000 description 1
- RAXVQVQRGUOQMA-UHFFFAOYSA-N 2-[3-[4-(2-hydroxy-6-methoxyphenyl)piperazin-1-yl]propyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione Chemical compound COC1=CC=CC(O)=C1N1CCN(CCCN2C(C3CC=CCC3C2=O)=O)CC1 RAXVQVQRGUOQMA-UHFFFAOYSA-N 0.000 description 1
- LOXFJPOTKVHHEI-UHFFFAOYSA-N 2-[3-[4-(2-hydroxy-6-methoxyphenyl)piperazin-1-yl]propyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione;hydrochloride Chemical compound Cl.COC1=CC=CC(O)=C1N1CCN(CCCN2C(C3CC=CCC3C2=O)=O)CC1 LOXFJPOTKVHHEI-UHFFFAOYSA-N 0.000 description 1
- ICPYAMKDSCBNAN-UHFFFAOYSA-N 2-[3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-methylpropyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione Chemical compound COC1=CC=CC=C1N1CCN(CC(C)CN2C(C3CC=CCC3C2=O)=O)CC1 ICPYAMKDSCBNAN-UHFFFAOYSA-N 0.000 description 1
- JHCQBMRDZXAWPL-UHFFFAOYSA-N 2-[3-[4-(2-methoxyphenyl)piperazin-1-yl]-2-methylpropyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione;hydrochloride Chemical compound Cl.COC1=CC=CC=C1N1CCN(CC(C)CN2C(C3CC=CCC3C2=O)=O)CC1 JHCQBMRDZXAWPL-UHFFFAOYSA-N 0.000 description 1
- UFASPPQQSNESRX-UHFFFAOYSA-N 2-[3-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione Chemical compound COC1=CC=CC=C1N1CCN(C(C)CCN2C(C3CC=CCC3C2=O)=O)CC1 UFASPPQQSNESRX-UHFFFAOYSA-N 0.000 description 1
- LECFCYMBNISEHK-UHFFFAOYSA-N 2-[3-[4-(2-methoxyphenyl)piperazin-1-yl]butyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione;hydrochloride Chemical compound Cl.COC1=CC=CC=C1N1CCN(C(C)CCN2C(C3CC=CCC3C2=O)=O)CC1 LECFCYMBNISEHK-UHFFFAOYSA-N 0.000 description 1
- GAYYZDMEYFKBEB-UHFFFAOYSA-N 2-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione Chemical compound COC1=CC=CC=C1N1CCN(CCCN2C(C3CC=CCC3C2=O)=O)CC1 GAYYZDMEYFKBEB-UHFFFAOYSA-N 0.000 description 1
- GOHGPCYOFOFLIG-UHFFFAOYSA-N 2-[3-[4-(3-chloro-4-methylphenyl)piperazin-1-yl]propyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione Chemical compound C1=C(Cl)C(C)=CC=C1N1CCN(CCCN2C(C3CC=CCC3C2=O)=O)CC1 GOHGPCYOFOFLIG-UHFFFAOYSA-N 0.000 description 1
- BLOFBNKYXWYKPG-UHFFFAOYSA-N 2-[3-[4-(3-chloro-4-methylphenyl)piperazin-1-yl]propyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione;hydrochloride Chemical compound Cl.C1=C(Cl)C(C)=CC=C1N1CCN(CCCN2C(C3CC=CCC3C2=O)=O)CC1 BLOFBNKYXWYKPG-UHFFFAOYSA-N 0.000 description 1
- AKFKDTSNGQQDCT-UHFFFAOYSA-N 2-[3-[4-(4-fluoro-2-methoxyphenyl)piperazin-1-yl]propyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione Chemical compound COC1=CC(F)=CC=C1N1CCN(CCCN2C(C3CC=CCC3C2=O)=O)CC1 AKFKDTSNGQQDCT-UHFFFAOYSA-N 0.000 description 1
- MTBGBYRWMLQVSZ-UHFFFAOYSA-N 2-[3-[4-(4-fluoro-2-methoxyphenyl)piperazin-1-yl]propyl]-3a,4,7,7a-tetrahydroisoindole-1,3-dione;hydrochloride Chemical compound Cl.COC1=CC(F)=CC=C1N1CCN(CCCN2C(C3CC=CCC3C2=O)=O)CC1 MTBGBYRWMLQVSZ-UHFFFAOYSA-N 0.000 description 1
- OVGGXHMQXIQOBR-UHFFFAOYSA-N 3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-amine Chemical compound COC1=CC=CC=C1N1CCN(CCCN)CC1 OVGGXHMQXIQOBR-UHFFFAOYSA-N 0.000 description 1
- UZTZKICRSWXRFQ-UHFFFAOYSA-N 3a,4,5,6-tetrahydroisoindole-1,3-dione Chemical compound C1CCC2C(=O)NC(=O)C2=C1 UZTZKICRSWXRFQ-UHFFFAOYSA-N 0.000 description 1
- QQXIZIWKCYUVGQ-UHFFFAOYSA-N 3a,4,5,6-tetrahydroisoindole-1,3-dione;hydrochloride Chemical compound Cl.C1CCC2C(=O)NC(=O)C2=C1 QQXIZIWKCYUVGQ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 206010005060 Bladder obstruction Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- BEHLMOQXOSLGHN-UHFFFAOYSA-N benzenamine sulfate Chemical compound OS(=O)(=O)NC1=CC=CC=C1 BEHLMOQXOSLGHN-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003666 myelinated nerve fiber Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical class C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
- 125000005543 phthalimide group Chemical class 0.000 description 1
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 229960002613 tamsulosin Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1097DE2000 | 2000-11-30 | ||
| PCT/IB2001/002261 WO2002044151A1 (en) | 2000-11-30 | 2001-11-29 | 1,4-disubstituted piperazine derivatives useful as uro-selective $g(a)1-adrenoceptor blockers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG107943A true BG107943A (bg) | 2004-08-31 |
Family
ID=11097130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG107943A BG107943A (bg) | 2000-11-30 | 2003-06-25 | 1,4-дизам...''...ни пип...разинови производни, пол...зни ка'о "ро'...л...к'ивни ал"а1-адр...но-...п'орни блок...ри |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6914064B2 (cs) |
| EP (1) | EP1339682A1 (cs) |
| JP (1) | JP2004514711A (cs) |
| KR (1) | KR20030068164A (cs) |
| CN (1) | CN1230423C (cs) |
| AP (1) | AP2003002810A0 (cs) |
| AR (1) | AR035930A1 (cs) |
| AU (2) | AU2231502A (cs) |
| BG (1) | BG107943A (cs) |
| BR (1) | BR0115865A (cs) |
| CA (1) | CA2430343A1 (cs) |
| CZ (1) | CZ20031698A3 (cs) |
| DO (1) | DOP2001000296A (cs) |
| EA (1) | EA006941B1 (cs) |
| EE (1) | EE200300250A (cs) |
| HU (1) | HUP0400545A3 (cs) |
| MA (1) | MA26064A1 (cs) |
| MX (1) | MXPA03004850A (cs) |
| NZ (1) | NZ526226A (cs) |
| OA (1) | OA12537A (cs) |
| PA (1) | PA8534001A1 (cs) |
| PL (1) | PL362210A1 (cs) |
| SK (1) | SK8052003A3 (cs) |
| WO (1) | WO2002044151A1 (cs) |
| ZA (1) | ZA200304242B (cs) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003084928A1 (en) * | 2002-04-08 | 2003-10-16 | Ranbaxy Laboratories Limited | Alpha, omega-dicarboximide derivatives as useful uro-selective α1α adrenoceptor blockers |
| AU2003278403A1 (en) * | 2003-10-15 | 2005-05-05 | Ranbaxy Laboratories Limited | 1-alkylpiperazinyl-pyrrolidin-2, 5-dione derivatives as adrenergic receptor antagonist |
| EP1746998A1 (en) * | 2004-03-22 | 2007-01-31 | Ranbaxy Laboratories, Ltd. | Combination therapy for lower urinary tract symptoms |
| WO2005113498A1 (en) * | 2004-05-19 | 2005-12-01 | Ranbaxy Laboratories Limited | Adrenergic receptor antagonists |
| WO2005118537A2 (en) * | 2004-05-31 | 2005-12-15 | Ranbaxy Laboratories Limited | Arylpiperazine derivatives as adrenergic receptor antagonists |
| WO2006018815A1 (en) * | 2004-08-16 | 2006-02-23 | Ranbaxy Laboratories Limited | Piperazine derivatives as adrenergic receptor antagonists |
| WO2006051374A2 (en) * | 2004-11-11 | 2006-05-18 | Ranbaxy Laboratories Limited | Arylpiperazines useful as adrenergic receptor antagonists |
| WO2006051399A1 (en) * | 2004-11-11 | 2006-05-18 | Ranbaxy Laboratories Limited | Piperazine derivatives useful as adrenergic receptor antagonists |
| WO2006092710A1 (en) * | 2005-03-02 | 2006-09-08 | Ranbaxy Laboratories Limited | Metabolites of 2-{3-[4-(2-isopropoxyphenyl) piperazin-1-yl]-propyl}-3a,4,7,7a-tetrahydro-1h-isoindole-1,3-(2h)-dione |
| WO2006117760A1 (en) * | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Adrenergic receptor antagonists |
| WO2007029156A2 (en) * | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Isoindoledione derivatives as adrenergic receptor antagonists |
| WO2007039809A1 (en) * | 2005-10-05 | 2007-04-12 | Ranbaxy Laboratories Limited | Metabolites of 2- {3-[4-(5-fluoro-2-isopropoxy-phenyl)-piperazin-1-yl]-propyl} -5,6-dihydroxy-hexahydro-isoindole-1,3-dione |
| JP5701213B2 (ja) | 2008-10-10 | 2015-04-15 | インスティチュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー．エル．エー．チャイナ | 新規なドーパミンｄ３受容体リガンド、その調製及び使用 |
| US9227944B2 (en) | 2008-10-10 | 2016-01-05 | Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China | Dopamine D3 receptor ligands and preparation and medical uses of the same |
| SG176553A1 (en) | 2009-05-05 | 2012-01-30 | Muthiah Manoharan | Lipid compositions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57197265A (en) * | 1981-05-29 | 1982-12-03 | Eisai Co Ltd | Carboxylic acid imide derivative, its preparation and medicament containing the same |
| JPS5936661A (ja) * | 1982-08-26 | 1984-02-28 | Eisai Co Ltd | カルボン酸イミド誘導体およびその製造方法ならびにそれを含有する医薬 |
| JPS5976059A (ja) * | 1982-10-21 | 1984-04-28 | Sumitomo Chem Co Ltd | 環状イミド誘導体及びその酸付加塩 |
| JPS5995267A (ja) * | 1982-11-25 | 1984-06-01 | Eisai Co Ltd | カルボン酸イミド誘導体およびその製造方法 |
| AT387773B (de) * | 1983-09-12 | 1989-03-10 | Bristol Myers Co | Verfahren zur herstellung von 1-heteroaryl-4-((2,5-pyrrolidindion-1-yl)aklyl) iperazin-derivaten |
| US4524206A (en) * | 1983-09-12 | 1985-06-18 | Mead Johnson & Company | 1-Heteroaryl-4-(2,5-pyrrolidinedion-1-yl)alkyl)piperazine derivatives |
| JPS60204784A (ja) | 1984-03-29 | 1985-10-16 | Eisai Co Ltd | カルボン酸イミド誘導体 |
| JP2918899B2 (ja) | 1989-03-09 | 1999-07-12 | 住友製薬株式会社 | 環状イミド誘導体の製造方法 |
| US5688795A (en) * | 1994-11-08 | 1997-11-18 | Syntex (U.S.A.) Inc. | 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy!-pyridine, pyrimidine and benzene derivatives as α1 -adrenoceptor antagonists |
| ATE201016T1 (de) * | 1995-06-09 | 2001-05-15 | Hoffmann La Roche | Pyrimidindion-, pyrimidintrion-, triazindion- derivate als alpha-1-adrenergische rezeptorantagonisten |
| WO1998037893A1 (en) | 1997-02-26 | 1998-09-03 | Sumitomo Pharmaceuticals Co., Ltd. | Dopamine d4 receptor antagonist |
| US6071915A (en) * | 1997-05-12 | 2000-06-06 | Ortho-Mcneil Pharmaceutical, Inc. | Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia |
| US6083950A (en) * | 1997-11-13 | 2000-07-04 | Ranbaxy Laboratories Limited | 1-(4-arylpiperazin-1-yl)-ω-[n-(α,ω-dicarboximido)]-alka nes useful as uro-selective α1-adrenoceptor blockers |
-
2001
- 2001-11-29 EP EP01998540A patent/EP1339682A1/en not_active Withdrawn
- 2001-11-29 OA OA1200300149A patent/OA12537A/en unknown
- 2001-11-29 SK SK805-2003A patent/SK8052003A3/sk not_active Application Discontinuation
- 2001-11-29 BR BR0115865-1A patent/BR0115865A/pt not_active IP Right Cessation
- 2001-11-29 CZ CZ20031698A patent/CZ20031698A3/cs unknown
- 2001-11-29 MX MXPA03004850A patent/MXPA03004850A/es unknown
- 2001-11-29 AU AU2231502A patent/AU2231502A/xx active Pending
- 2001-11-29 KR KR10-2003-7007305A patent/KR20030068164A/ko not_active Withdrawn
- 2001-11-29 CA CA002430343A patent/CA2430343A1/en not_active Abandoned
- 2001-11-29 AU AU2002222315A patent/AU2002222315B2/en not_active Ceased
- 2001-11-29 EA EA200300620A patent/EA006941B1/ru not_active IP Right Cessation
- 2001-11-29 CN CNB018220460A patent/CN1230423C/zh not_active Expired - Fee Related
- 2001-11-29 PA PA20018534001A patent/PA8534001A1/es unknown
- 2001-11-29 HU HU0400545A patent/HUP0400545A3/hu unknown
- 2001-11-29 JP JP2002546521A patent/JP2004514711A/ja not_active Withdrawn
- 2001-11-29 PL PL01362210A patent/PL362210A1/xx not_active Application Discontinuation
- 2001-11-29 EE EEP200300250A patent/EE200300250A/xx unknown
- 2001-11-29 NZ NZ526226A patent/NZ526226A/en unknown
- 2001-11-29 WO PCT/IB2001/002261 patent/WO2002044151A1/en not_active Ceased
- 2001-11-29 AP APAP/P/2003/002810A patent/AP2003002810A0/en unknown
- 2001-11-30 DO DO2001000296A patent/DOP2001000296A/es unknown
- 2001-11-30 US US09/998,115 patent/US6914064B2/en not_active Expired - Fee Related
- 2001-11-30 AR ARP010105588A patent/AR035930A1/es not_active Application Discontinuation
-
2003
- 2003-05-30 ZA ZA200304242A patent/ZA200304242B/en unknown
- 2003-05-30 MA MA27188A patent/MA26064A1/fr unknown
- 2003-06-25 BG BG107943A patent/BG107943A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL362210A1 (en) | 2004-10-18 |
| AU2002222315B2 (en) | 2007-06-21 |
| NZ526226A (en) | 2004-05-28 |
| PA8534001A1 (es) | 2002-12-11 |
| EP1339682A1 (en) | 2003-09-03 |
| CZ20031698A3 (cs) | 2003-11-12 |
| DOP2001000296A (es) | 2003-03-15 |
| BR0115865A (pt) | 2003-12-23 |
| ZA200304242B (en) | 2004-03-02 |
| AP2003002810A0 (en) | 2003-06-30 |
| EE200300250A (et) | 2003-10-15 |
| SK8052003A3 (en) | 2003-12-02 |
| MXPA03004850A (es) | 2004-01-26 |
| US6914064B2 (en) | 2005-07-05 |
| JP2004514711A (ja) | 2004-05-20 |
| HUP0400545A3 (en) | 2007-05-02 |
| CA2430343A1 (en) | 2002-06-06 |
| WO2002044151A1 (en) | 2002-06-06 |
| US20020156085A1 (en) | 2002-10-24 |
| EA200300620A1 (ru) | 2003-12-25 |
| KR20030068164A (ko) | 2003-08-19 |
| MA26064A1 (fr) | 2004-04-01 |
| AR035930A1 (es) | 2004-07-28 |
| CN1486300A (zh) | 2004-03-31 |
| EA006941B1 (ru) | 2006-06-30 |
| CN1230423C (zh) | 2005-12-07 |
| AU2231502A (en) | 2002-06-11 |
| HUP0400545A2 (hu) | 2004-07-28 |
| OA12537A (en) | 2006-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6083950A (en) | 1-(4-arylpiperazin-1-yl)-ω-[n-(α,ω-dicarboximido)]-alka nes useful as uro-selective α1-adrenoceptor blockers | |
| CA2233003A1 (en) | Pyrimidine derivatives as 5ht2c-receptor antagonists | |
| SK73494A3 (en) | Isatin derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | |
| US6914064B2 (en) | 1,4-Disubstituted piperazine derivatives useful as uro-selective α1-adrenoceptor blockers | |
| AU2002222315A1 (en) | 1,4-disubstituted piperazine derivatives useful as uro-selective alpha1-adrenoceptor blockers | |
| CZ265994A3 (en) | Derivatives of 1-/2h-1-benzopyran-2-on-8-yl/piperazine, process of their preparation pharmaceutical compositions containing thereof as active components and their use | |
| PT750614E (pt) | Derivados de amino-quinazolinilo que possuem actividade antagonista alfa | |
| AU2002253429A1 (en) | ALPHA, OMEGA-DICARBOXIMIDE DERIVATIVES AS USEFUL URO-SELECTIVE Alpha1Alpha ADRENOCEPTOR BLOCKERS | |
| FI65998C (fi) | Foerfarande foer framstaellning av nya farmakologiskt aktiva pyrrolyl-pyridazinaminderivat | |
| NZ249217A (en) | Indole and 2-oxo-benzimidazole derivatives and medicaments | |
| US4647565A (en) | 2-(2-quinazolinylaminoalkoxymethyl)-1,4-dihydropyridine derivatives as cardiovascular agents | |
| CZ2001235A3 (cs) | Arylpiperazinové deriváty vhodné jako uroselektivní alfa 1-adrenoceptorové blokátory | |
| JP4021481B2 (ja) | 抗ガストリン活性を持つ芳香族酸ジアミド類、その製造法および医薬用途 | |
| AU763541B2 (en) | Arylpiperazine derivatives useful as uroselective alpha1-adrenoceptor blockers | |
| EP0743946A1 (en) | 5ht2b receptor antagonists condensed indoles | |
| JP3987113B2 (ja) | 抗高血圧活性を有する新規キナゾリン―４―アミノ―２―（ピペリジン―１―イル―４―置換）誘導体並びにその製造法および医薬用途 | |
| US4526898A (en) | Antihypertensive 4-(2-imidazolin-2-yl-amino)-2-methyl-indazole | |
| JP2005532282A (ja) | 有用な泌尿ー選択性α１Ａアドレノレセプターブロッカーとしてのカルボキシイミド体 | |
| CS202071B2 (cs) | Způsob přípravy 2-(4-substituovaných piperazin-1-yl)-4-amino-6,7- -dimethoxychinazolinů | |
| JP2002521362A (ja) | ウロ選択性α１−アドレノセプターブロッカーとして有用なアリルピペラジン誘導体 |